Navigation Links
PAREXEL and Salem State University Launch Clinical Trial Management Graduate Program

WALTHAM, Mass., Sept. 20, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced a partnership with Salem State University to offer a Post Graduate Certificate Program in Clinical Trial Management.  This collaboration will provide candidates with the education needed to succeed in the growing clinical research management industry.

PAREXEL is committed to developing the future biopharmaceutical workforce with courses specifically tailored to meet the growing talent needs of the clinical development job market. Salem State University is an ideal partner to help further this effort due to its experience in developing academic programs relevant to workforce needs in the healthcare and life science fields.

"Salem State has a progressive outlook in partnering with industries and an impressive track record in building career interest in science disciplines," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. "PAREXEL has experienced rapid growth in the United States and we are excited to have a major university partner in the Northeast to further develop the much-needed talent pool of candidates in the field."

"Our partnership with PAREXEL International is a strong example of Salem State's commitment to working with industry to create workforce aligned programs," said Patricia Maguire Meservey, president of Salem State University. "There is a clear need here for people with a healthcare or life sciences background who, with the right training, can tap into a specialized area where there is great demand." 

PAREXEL has a well-established history of developing close partnerships with regional universities through its PAREXEL Academy. The company established the first academy of its kind in Berlin, Germany in 2001, where candidates can earn a Bachelor of Science (BSc) in Clinical Research degree validated and awarded by the University of Wales. More recently, PAREXEL entered into an agreement with the National University of Singapore (NUS), through its National University of Singapore Academy of GxP Excellence (NUSAGE), to offer an academic program to help meet the increasing demand for talent in the field of clinical research in the Asia region. Since its inception, PAREXEL International has helped train more than one thousand professionals and has successfully placed many of its graduates into the life sciences industry segment. 

About Salem State UniversitySalem State University, established in 1854, is a comprehensive, public institution of higher learning located approximately 15 miles north of Boston, Massachusetts. The university enrolls over 10,000 undergraduate and graduate students representing 27 states and 57 nations, and is one of the largest state universities in the Commonwealth of Massachusetts.

About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 51 countries around the world, and has approximately 12,695 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2012 as filed with the SEC on August 27, 2012, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark and PAREXEL MyTrials is a trademark of PAREXEL International Corporation and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged. Contacts:Georgina Cattaway, Director Marketing

Kim Leadley/Sarah BrucknerPAREXEL International

PAN CommunicationsTel: +44 1895 614530

Tel: +1 617-502-4300Email:


SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
2. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
3. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
4. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
5. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
6. PAREXEL International To Present At NASDAQ OMX Investor Conference
7. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2012 Earnings Release and Conference Call
8. PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
9. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
10. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
11. PAREXEL International to Present at Robert Baird Healthcare Conference
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... ... CBD College is proud to announce that on November 20th, ... its Diagnostic Medical Sonography program. CBD College is honored to join this very short ... universities in the state of California make the cut. CBD College is officially the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Dr. Thomas ... Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph ... that both STEMI and Sepsis conditions present in similar ways and require time-critical intervention ...
Breaking Medicine News(10 mins):